News

We did it again!

We are proud to announce our successful re-certification according to DIN EN ISO 13485 – the internationally recognized standard for quality management systems in medical device development and services.

This achievement reflects our ongoing commitment to quality, safety, and continuous improvement in everything we do – from innovative imaging solutions to reliable clinical data services.

A big thank you to our dedicated team whose expertise and passion made this possible. Together, we’re shaping the future of medical technology with precision and trust.

mediri x Wemedoo – A Strategic Partnership for Imaging-Based Trials

We’re excited to announce our partnership with Wemedoo, a forward-thinking company transforming clinical data management.

By integrating our mTRIAL platform with Wemedoo’s oomnia, we’re enabling research teams to access real-time imaging analysis, browser-based scan review, and protocol-driven workflows – all in one seamless system.

This collaboration marks a significant step toward our shared vision: empowering sponsors, CROs, and academic researchers with full control over their clinical and imaging data – without the friction of disconnected tools.

Smarter trials. Fewer silos. One connected system.

Read more

The new ICH E6(R3) guideline marks a major shift in how clinical trials are designed, conducted, and monitored — with a strong focus on quality by design, risk-based approaches, and digital innovation.

At mediri, we’re ready.
As a partner for imaging-based clinical trials, we welcome the updated framework, which emphasizes:

• Data integrity and traceability across digital systems
• Patient-centric trial design, including decentralized elements
• Fit-for-purpose quality management
• Clearer roles for service providers like imaging CROs

Our imaging platforms and AI-supported analysis tools are already aligned with these principles — helping sponsors meet regulatory expectations while improving trial efficiency and data quality.

Whether you’re planning a new study or adapting to E6(R3), we’re here to support your transition.

Tired of juggling multiple vendors and complex workflows? Discover how one partner can simplify it all.
We support your imaging clinical trials with tailored, end-to-end solutions – combining expertise, innovation, and reliability.

• Site management & coordination
• Central image reading & quality control
• AI-powered workflows via our secure cloud platform mTRIAL
• Data hosting in Germany for maximum security & GDPR compliance

Whether you’re planning multi-center trial or need a reliable imaging core lab, mediri is here to support you every step of the way.

Let’s streamline your workflow – from scan to submission – with one trusted partner.
Get in touch to explore how we can support your success.

What carriage driving has taught me about managing clinical studies:
I’ve worked with horses for as long as I can remember, and the mindset they’ve taught me continues to shape how I lead teams and manage clinical studies. Here are a few lessons from behind the reins that translate surprisingly well into the workplace:

Think two steps ahead
When driving horses, you must anticipate potential risks before they do. Being proactive—not just reactive—is crucial. It’s the same in study management: foresight helps you steer your team through challenges smoothly.

See through their eyes
Horses are prey animals with a strong flight instinct. Understanding how they perceive the world teaches you to shift perspective—an essential skill when working with diverse teams and stakeholders.

Stay connected, but give space
Your only link to the horses is the reins. You need steady contact to guide them—but also enough slack to let them move freely. Leading people requires the same balance: support and direction, without micromanaging.

What’s the story behind your mindset at work?

How can features from different MRI sequences be combined with AI models to support more precise diagnosis in breast cancer?

We are excited to share that our PhD Student Yaqeen Ali presented his recent work “Leveraging MRI Radiomics and Machine Learning for Accurate Differentiation of Triple-Negative Breast Cancer Subtype” at the International Symposium on Computer Based Medical Systems (CBMS) 2025 Conference in Madrid!

This research is part of the BosomShield project at mediri GmbH, and contributes to his PhD at Darmstadt University of Applied Sciences supervised by Prof. Johannes Gregori.

Imaging with Integrity: Creating Digital Trust from Day One

In clinical trials, patient centricity doesn’t stop at electronic consent—it begins there.

At mediri, we believe that true engagement continues through every step of the imaging journey. From site setup to central read, our integrated approach ensures that patients remain supported, data remains secure, and compliance becomes a natural outcome of thoughtful design.

With our mTRIAL platform, we enable:

• Real-time feedback and transparent communication
• AI-supported quality assurance for imaging data
• Seamless, secure data exchange across multicentre trials
• Custom workflows that align with study protocols and patient needs

By transforming imaging compliance into a patient-first experience, we help sponsors and sites build trust, improve data quality, and accelerate outcomes.

From consent to connection. From data to trust.

Let’s rethink the imaging journey—together.

How does your team ensure patient engagement beyond the consent form?

How can ASL help visualize tumor aggressiveness in IDH-wildtype glioblastomas?
By quantifying cerebral blood flow (CBF) and permeability (Tex)—non-invasively.
IDH-wildtype glioblastomas (WHO Grade 4) are among the most aggressive brain tumors, characterized by high vascularity and increased blood-brain barrier (BBB) permeability. Arterial Spin Labeling (ASL) MRI could offer a way to visualize these characteristics without the need for contrast agents—potentially benefiting long-term monitoring and patient safety.

We support clinical and oncological research with a comprehensive ASL solution, Our approach includes:
– Scientific consulting for study design and imaging protocols
– Installation of advanced multi-TE ASL sequences
– Quantitative analysis of CBF, ATT, and Tex—a potential marker for BBB integrity
– Secure, pseudonymized data handling via our platform mTRIAL

Why this matters in glioblastoma research?
ASL enables the detection of hyperperfusion in tumor regions—often correlating with tumor grade and aggressiveness. The Tex parameter provides additional insight into BBB disruption, which is typical in high-grade gliomas and may influence drug delivery and treatment response. This makes ASL a powerful tool for non-invasive tumor characterization and therapy monitoring.

Whether you’re conducting a clinical trial or exploring new imaging biomarkers, we are your partner for integrating ASL into neuro-oncological research.
Let’s advance brain tumor imaging—safely, precisely, and without contrast.

We’re proud to share a new scientific publication by our CEO, Prof. Matthias Günther!
His latest article in Magnetic Resonance in Medicine describes gammaSTAR, a powerful, vendor-independent MR sequence development platform with real-time feedback capabilities.

What makes gammaSTAR unique?
The framework enables:

• Rapid development of advanced MR sequences using a modular architecture (Python, Lua, vendor-specific drivers)
• Real-time feedback integration for applications like prospective motion correction
• Seamless execution of complex sequences (e.g., pCASL GRASE, 3D radial UTE) without long preparation times
• High reproducibility across scanners at 1.5T and 3T, with image quality comparable to leading vendors

In vivo results show:

• Excellent agreement in image contrast and ADC values
• Significant reduction in motion artifacts (voxel displacement reduced from 1.63 mm to 0.37 mm with correction)
• Compatibility with standard vendor reconstruction pipelines

This important work is part of our SIMAB project, a collaboration with @Fraunhofer MEVIS, funded by the German Federal Ministry of Education and Research. Together, we are developing a vendor-agnostic MR sequence framework to enable consistent, high-quality imaging in multicenter clinical trials—regardless of scanner type.

At mediri, we are committed to making imaging in clinical trials more reliable, reproducible, and patient-centric.
– Innovation through collaboration
– Imaging that connects
– Trust in every scan

Read the full publication here:
👉 https://pubmed.ncbi.nlm.nih.gov/40391628/

Sometimes, medical images want to be seen in a different light …

On this International Clinical Trials Day, we appreciate the progress made in clinical research – and the vital role that advanced medical imaging plays in shaping tomorrow’s therapies.

As imaging CRO, we specialize in cutting-edge imaging solutions that support clinical trials across the globe. From AI-assisted analysis support to centralized image read and data management, our work ensures that imaging biomarkers are not just captured – but truly understood.

Clinical trials are the backbone of medical innovation. By integrating precise, high-quality imaging into study workflows, we help researchers gain deeper insights, accelerate decision-making, and ultimately bring life-changing treatments to patients faster.
Together, we’re shaping the future of medicine!